The Cancer Letter

Johns Hopkins investigators create open source database to more easily study cancer data - The Cancer Letter Researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types of cancer data—including laboratory results, genetic sequencing and imaging data—in one setting. To access this subscriber-only content please log in or subscribe.If your institution has a […]

Johns Hopkins investigators create open source database to more easily study cancer data
https://cancerletter.com/clinical-roundup/20260306_8c/

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - The... If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with […]

The company’s press release about the result of NHS-Galleri does acknowledge that the National Health Service trial of Galleri had missed its primary endpoint—reduction in stage 3 and stage 4 cancers.
https://cancerletter.com/news-analysis/20260306_1/

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.” Castle is “disappointed” by Galleri results but not discouraged by implications... Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for […]

"Fundamentally, we wanted GRAIL to succeed, because we’re public health scientists. Nobody wants to get cancer and nobody wants to die from it," said Philip Castle, director of NCI's Division of Cancer Prevention.
https://cancerletter.com/conversation-with-the-cancer-letter/20260306_3/

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute - The Cancer Letter Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon were appointed members of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site […]

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute
(@mdanderson.bsky.social)
https://cancerletter.com/in-brief/20260306_7c/

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds - The Cancer Letter A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially for those with very low PSA levels before treatment. To access this subscriber-only content please log in or subscribe.If your institution has a site […]

Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, UCLA-led study finds
https://cancerletter.com/clinical-roundup/20260306_8b/

Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68 - The Cancer Letter Erin Geddis Cummings , advocate and founder of Hodgkin’s International, died on Feb. 24, at Martha’s Vineyard Hospital, surrounded by her family. She was 68. Her death was a result of stomach cancer, complicated by the long-term effects of her childhood battle with cancer. Erin was born in Summit, New Jersey, in 1957 to Donald […]

"Diagnosed with Hodgkin’s lymphoma at 15, Erin lived more than 50 years with and beyond cancer," Cancer Nation writes. "She carried the long arc of survivorship in her own body. And she never looked away from that truth."
https://cancerletter.com/obituary/20260306_4/

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment - The Cancer Letter Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment. The transcript of the conversation follows. Why is AI important in cancer research and treatment? Artificial intelligence (AI) is poised to fundamentally […]

Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment.
https://cancerletter.com/sponsored-article/20260306_5/

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery
https://cancerletter.com/drugs-and-targets/20260306_9c/

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg... Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log […]

“We're really excited about it despite the missed primary endpoint, and we're excited enough that we announced publicly that we're expanding our sales and medical teams in response to this," Megan Hall of GRAIL said.
https://cancerletter.com/conversation-with-the-cancer-letter/20260306_2/

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.” Castle is “disappointed” by Galleri results but not discouraged by implications... Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for […]

NCI's Philip Castle said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers—but is still hopeful for the future of MCDs.
https://cancerletter.com/conversation-with-the-cancer-letter/20260306_3/

FDA grants tentative approval for Lutetium Lu 177 dotatate - The Cancer Letter FDA has granted tentative approval for the Abbreviated New Drug Application for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent version of Lutathera (lutetium Lu 177 dotatate), which is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors. To access this subscriber-only content please log in or subscribe.If […]

FDA grants tentative approval for Lutetium Lu 177 dotatate
https://cancerletter.com/drugs-and-targets/20260306_9b/

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds - The Cancer Letter Colorectal cancer rates in the U.S. are moving in two very different directions, according to a report released from the American Cancer Society. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in […]

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds
(@americancancersoc.bsky.social)
https://cancerletter.com/clinical-roundup/20260306_8a/

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - The... If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with […]

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
https://cancerletter.com/news-analysis/20260306_1/

Bob Gray steps down as ECOG-ACRIN group statistician - The Cancer Letter Bob Gray has retired from his role as Group Statistician, Therapeutics, for the ECOG-ACRIN Cancer Research Group, as of Feb. 28. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login […]

Bob Gray steps down as ECOG-ACRIN group statistician
https://cancerletter.com/in-brief/20260306_7b/

House member introduces bill to increase funding for MCD testing of firefighters - The Cancer Letter Rep. Josh Gottheimer (D-NJ) introduced the FIRE Cancer Act on Feb. 27. The piece of legislation seeks to increase grant dollars available to local fire departments, specifically earmarked for cancer prevention, “including providing multi-cancer early detection testing or other forms of preventative tests.” To access this subscriber-only content please log in or subscribe.If your institution […]

House member introduces bill to increase funding for MCD testing of firefighters
https://cancerletter.com/cancer-policy/20260306_6b/

NCI Trials for March - The Cancer Letter The National Cancer Institute approved the following clinical research studies last month. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe

NCI Trials for March 2026
https://cancerletter.com/nci-trials/20260306_10/

FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM - The Cancer Letter FDA has approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in […]

FDA approves teclistamab + daratumumab hyaluronidase-fihj for r/r MM
https://cancerletter.com/drugs-and-targets/20260306_9a/

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg... Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log […]

GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ
https://cancerletter.com/conversation-with-the-cancer-letter/20260306_2/

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment - The Cancer Letter Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment. The transcript of the conversation follows. Why is AI important in cancer research and treatment? Artificial intelligence (AI) is poised to fundamentally […]

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment
By John’s Hopkins Kimmel Cancer Center Communications
https://cancerletter.com/sponsored-article/20260306_5/

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment - The Cancer Letter Vasan Yegnasubramanian, MD, PhD, is the director of Precision inHealth Medicine at Johns Hopkins. He spoke with Johns Hopkins Kimmel Cancer Center communications staff about how AI is transforming cancer research and treatment. The transcript of the conversation follows. Why is AI important in cancer research and treatment? Artificial intelligence (AI) is poised to fundamentally […]

Vasan Yegnasubramanian: How AI is transforming cancer research and treatment
https://cancerletter.com/sponsored-article/20260306_5/

Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68 - The Cancer Letter Erin Geddis Cummings , advocate and founder of Hodgkin’s International, died on Feb. 24, at Martha’s Vineyard Hospital, surrounded by her family. She was 68. Her death was a result of stomach cancer, complicated by the long-term effects of her childhood battle with cancer. Erin was born in Summit, New Jersey, in 1957 to Donald […]

Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68
https://cancerletter.com/obituary/20260306_4/

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - The... If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with […]

GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis
https://cancerletter.com/news-analysis/20260306_1/

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition - The Cancer Letter W. Kimryn Rathmell, CEO of the James Cancer Hospital and Solove Research Institute, has also been named director of The Ohio State University Comprehensive Cancer Center in place of former Director Raphael E. Pollock, who has stepped down from the position he had held since November 2017 to become OSUCCC director emeritus. To access this […]

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
https://cancerletter.com/in-brief/20260306_7a/

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members - The Cancer Letter Mount Sinai hospital has formed a committee to investigate the ties between Jeffrey Epstein and Eva Dubin a leading doctor at the hospital and founder of the Dubin Breast Center at the Tisch Cancer Institute whose name is featured prominently in the Epstein files. To access this subscriber-only content please log in or subscribe.If your […]

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
https://cancerletter.com/cancer-policy/20260306_6a/

NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.” Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
https://cancerletter.com/conversation-with-the-cancer-letter/20260306_3/

ROSELLA phase III trial of relacorilant in platinum-resistant ovarian cancer meets OS primary endpoint - The Cancer Letter ROSELLA phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival primary endpoint. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login […]

ROSELLA phase III trial of relacorilant in platinum-resistant ovarian cancer meets OS primary endpoint
https://cancerletter.com/clinical-roundup/20260227_8d/

The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient “Diverse ecosystems are more robust than non-diverse ecosystems. That is a biological fact.” - The Cancer... “We’ve always argued that money comes and goes, but if you lose a generation of scientists—you can’t buy them back,” said Kelvin Lee, director of the Indiana University Simon Comprehensive Cancer Center. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for […]

“We are very cognizant that there are rural communities that are being left behind. So, the question is how do we impact that? How do we actually get out there?" Kelvin Lee, director of the Indiana University Simon Comprehensive Cancer Center.
https://cancerletter.com/podcastc/20260227_1/

Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE “Deidentified” ≠ “deidentifiable” - The Cancer Letter Two lawsuits filed within days of each other in the U.S. District Court for the Northern District of Illinois claim that Tempus AI Inc. had violated the Illinois Genetic Information Privacy Act when it acquired Ambry Genetics and started to integrate its genetics data into its predictive models. To access this subscriber-only content please log […]

"How we access, govern, and apply data across cancer centers—and in collaboration with national data partners—will define the next decade of oncology," Sorena Nadaf-Rahrov says about the Tempus AI lawsuits.
https://cancerletter.com/the-cancer-letter/20260227_2/

Bob Purcell named chief communications officer at PICI - The Cancer Letter Bob Purcell was named chief communications officer at The Parker Institute for Cancer Immunotherapy. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe

Bob Purcell named chief communications officer at PICI
https://cancerletter.com/in-brief/20260227_7d/

After a year, Stephenson institute sees a broader role in funding pancreatic cancer research, fostering collaborations “We are not just funding research. We are building a trusted community.” - The... The Stephenson Global Pancreatic Cancer Research Institute, established a little over a year ago with a $150 million gift from entrepreneurs and philanthropists A. Emmet Stephenson Jr. and Tessa Stephenson Brand, has refined its goals. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login […]

"One of the most remarkable aspects of this meeting was the depth of trust in the room," says Jennifer Kim of the Stephenson Global Pancreatic Cancer Research Institute annual symposium.
https://cancerletter.com/the-cancer-letter/20260227_4/